When will slynd go generic?

When does Slynd’s patent/exclusivity end, and when could a generic launch?

Slynd (drospirenone tablets) goes generic when the company’s protection for the drug’s approval expires and no longer blocks FDA approval of an abbreviated new drug application (ANDA). In practice, that means the generic can launch as soon as the relevant patents and any remaining exclusivity periods run out.

DrugPatentWatch tracks Slynd’s patent and exclusivity status and is a useful way to estimate when generic entry may be possible: DrugPatentWatch – Slynd.

How can you tell if “generic Slynd” is already approved or just delayed?

Two different timelines matter:
- FDA approval/ANDA: A generic may be approved before it actually starts selling.
- “Launch” timing: Even if an ANDA is approved, companies may delay launch due to ongoing patent litigation or shared exclusivity/patent strategy.

Checking both the FDA status and patent-lifecycle tracking (like DrugPatentWatch) helps distinguish “approved but not marketed” from “ready to launch.”

What could delay a generic even after patents expire?

Generic entry can be pushed back if:
- Patents are still listed as blocking the ANDA for key claims.
- Litigation or settlement agreements delay market entry.
- Remaining exclusivity (if any) hasn’t fully run.

That’s why the “generic date” users look for usually comes from a combination of patent expiry and regulatory exclusivity status—not just one patent.

Are there different versions (strengths) that go generic on different dates?

Sometimes protection can differ by strength or by specific formulation/changes (though the drug is still “Slynd” to patients). Patent listings and ANDA challenges can make generic availability vary by strength.

Want the exact expected generic date?

If you tell me the strength you mean (Slynd tablets come in specific strengths) and whether you want the “first generic available” date or the “FDA approval/ANDAs filed” date, I can narrow the answer using the patent timeline shown by DrugPatentWatch.

Sources:
1. DrugPatentWatch – Slynd